» Articles » PMID: 18358497

Agonist-specific Down Regulation of Mu-opioid Receptors: Different Cellular Pathways Are Activated by Different Opioid Agonists

Overview
Journal Life Sci
Publisher Elsevier
Date 2008 Mar 25
PMID 18358497
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Opioid agonists are known to induce down regulation of opioid receptors through the classical pathway that involves phosphorylation, clathrin-dependent endocytosis and lysosomal/endosomal degradation of the internalized receptors. As expected, exposure of mu-opioid receptor (MOR)-transfected HEK-293 cells to either DAMGO (a specific mu-opioid agonist) or etorphine (a wide spectrum opioid agonist) resulted in down regulation of the receptors that was blocked by the kinase inhibitor staurosporine, by hypertonic sucrose and by the lysosomal and proteasomal inhibitors chloroquine and lactacystin. High concentration of etorphine, but not of DAMGO, induced an additional process of down regulation that was resistant to staurosporine, to hypertonic sucrose and to chloroquine-lactacystin. Etorphine, but not DAMGO, also induced down regulation of mu-opioid receptors in isolated membranes of HEK cells. This membrane-delimited down regulation was blocked by selective inhibitors of protease enzymes, suggesting the involvement of membranous serine- and amino-peptidases. This membranous down regulation of opioid receptors was dependent on the concentration of etorphine and was blocked by the opioid antagonist naloxone. Etorphine induced similar down regulation in membranes of HEK-293 cells transfected with delta-opioid receptors (DOR) as well in membranes of cells that endogenously express opioid receptors. This agonist-specific membrane-delimited regulatory process appears to be physiologically relevant and should be taken into account when studying long term effects of opioid drugs.

Citing Articles

MicroRNA 339 down-regulates μ-opioid receptor at the post-transcriptional level in response to opioid treatment.

Wu Q, Hwang C, Zheng H, Wagley Y, Lin H, Kim D FASEB J. 2012; 27(2):522-35.

PMID: 23085997 PMC: 3545525. DOI: 10.1096/fj.12-213439.


Heteromerization of the μ- and δ-opioid receptors produces ligand-biased antagonism and alters μ-receptor trafficking.

Milan-Lobo L, Whistler J J Pharmacol Exp Ther. 2011; 337(3):868-75.

PMID: 21422164 PMC: 3097170. DOI: 10.1124/jpet.111.179093.


Dual neuroprotective and neurotoxic effects of cannabinoid drugs in vitro.

Bologov A, Gafni M, Keren O, Sarne Y Cell Mol Neurobiol. 2010; 31(2):195-202.

PMID: 21052827 PMC: 11498440. DOI: 10.1007/s10571-010-9604-y.


Long-term morphine treatment decreases the association of mu-opioid receptor (MOR1) mRNA with polysomes through miRNA23b.

Wu Q, Zhang L, Law P, Wei L, Loh H Mol Pharmacol. 2009; 75(4):744-50.

PMID: 19144786 PMC: 2684920. DOI: 10.1124/mol.108.053462.